The present invention relates to a composition and method for treatment of patients afflicted with fibromyalgia. More particularly, this invention is directed to a composition and method for relieving Symptoms associated with chronic fibromyalgia in human patients by administering low doses of interferon.
BACKGROUND AND SUMMARY OF THE INVENTION
Fibromyalgia is a common disabling disorder character ized by chronic musculoskeletal aches and pain, Stiffness, general fatigue, and Sleep abnormalities including dimin ished Stage four Sleep. Examination of affected patients reveals increased tenderneSS at muscle and tendon insertion Sites, known as "tender points. Fibromyalgia patients expe rience Severe morning StiffneSS and a generalized decreased of overall physical function, and they are often prone to headaches, memory and concentration problems, dizziness, numbness and tingling, and crampy abdominal or pelvic pain. Fibromyalgia affects 2-4% of the population and is most frequently found in women between 20 and 50 years old, though it can also affect men, the elderly and minors.
Diagnosis of fibromyalgia is often overlooked due to the general nature of the Symptoms and the lack of diagnostic lab or X-ray abnormalities. The disorder is often concomitant with, masked by or confused with other diseaseS Such as rheumatoid arthritis, chronic fatigue Syndrome or irritable bowl Syndrome. A physician can positively diagnosis fibro myalgia Syndrome by finding the Symptoms of generalized musculoskeletal pain and pain at more than 11 of 18 defined characteristic "tender points' when finger preSSure of about 4 kg is applied to the area, which test is known as the "tender point indeX'.
Currently the best treatment available for fibromyalgia consists of a combination of analgesics, sleep aids, exercise programs emphasizing Stretching and cardiovascular fitness, relaxation techniques and other measures to reduce muscle tension, and educational programs to reduce emotional and physical StreSS. Numerous pharmaceutical regimes have been tried including treatment with Serotonin modulators and antisera to endogenous psychoactive agents. Therapeu tic response can be assessed by the reduction of pain in the tender point indeX and improvement in Several generalized criteria Such as physical function, Stiffness, fatigue, depression, tenseness, etc. Responses to these various thera pies have proven variable within a patient pool and have rarely exceeded modest relief of Some Symptoms. Often, initial therapeutic gains are temporary with the long term outcome marginally if at all distinguishable from placebo results.
There exists a significant need for more effective therapy for patients afflicted with fibromyalgia. The present inven tion is directed to a method for treating the disease condition (as measured by reduction of clinical Symptoms) by treating a fibromyalgia afflicted patient with low doses of interferon administered either bucally, Sublingually or by oral inges tion. In one embodiment a Type I interferon is administered in a Solid or liquid dosage form by oral ingestion, or it is administered to the oral and pharyngeal mucosa of a patient diagnosed with fibromyalgia at a dose of about 1 to about 1500 IU interferon per day, more preferably, about 5 to about 1000 IU per day. In another embodiment interferon is 2 administered orally in doses of about 10 to about 250 IU per day. In another embodiment, interferon administered is about 15 to about 150 IU per day. The daily doses can be divided into multiple dosages forms administered two or 5 more times per day.
Interferon for oral ingestion administration in accordance with the present invention can be formulated using art recognized techniques into pharmaceutically acceptable liq uid carriers or in combination with pharmaceutically accept 10 able Solid carriers in the form of tablets, capsules, caplets, or gel-Seals. Interferon for buccal or Sublingual administration to the patient's oral and pharyngeal mucosa can be formulated in liquid forms or in Solid forms using a Saliva Soluble carrier to form saliva soluble solid dosage forms which can be held in the mouth for a time Sufficient to dissolve the dosage form and form an interferon-containing Saliva Solution in contact with the patient's oral and pharyngeal mucosa to Stimulate a therapeutic effect. The clinical agent of choice for use in treatment in accordance with the present invention is human leucocyte interferon (human interferon-alpha) produced by art recog nized procedures. Interferon-alpha can be mass produced by collection and purification of quantities of human buffy coat leukocytes, induction of interferon production with Virus, and isolation from culture media; or interferon-alpha can be produced, for example, in accordance with the procedures described and claimed in U.S. Pat. No. 4,276,282, the disclosure which is incorporated herein by reference. Such interferon-alpha for use in accordance with this invention is commercially available. Also acceptable for use in accor dance with the present invention are human interferon-alpha compositions produced by recombinant DNA technology and commercially available from Schering-Plough (Intron(R), Hoffmann-LaRoche (Roferon(R) and AmGen (Infergen(R).
In one embodiment of this invention, the method for treating fibromyalgia comprises the Step of orally adminis tering to a patient afflicted with that disease about 0.01 to about 5.0 IU/lb patient body weight per day, more preferably about 0.25 to about 1.5 IU/lb patient body weight per day of interferon-alpha for relief of one or more Symptoms of the disease. The interferon-alpha can be of heterologous (non human) or homologous (human) origin, it can be formulated in a liquid or Solid dosage form, and it can be administered by oral ingestion administration or by buccal or Sublingual administration.
The interferon intended for buccal or sublingual admin istration in accordance with the present invention is admin istered to the patient in a dosage form adapted to promote contact of the administered interferon with the patients oral and pharyngeal mucosa. Thus, the dosage form can be in the form of an interferon-containing Solution or Syrup to be administered and used by the patient in a manner which promotes contact of the interferon component with oral mucosal tissues, for example, by holding the interferon Solution in the mouth for up to one or two minutes. Preferably, the interferon for use in the present invention is formulated into a Solid dosage form comprising the low dose of interferon, for example, interferon-alpha and a Saliva Soluble carrier optionally with desirable excipients, Such as buffers, or tableting aids. The Solid dosage form is formu lated to dissolve, when held in a patient's mouth, to form a Saliva Solution of the dose of interferon to promote contact of the interferon with the oral and pharyngeal mucosa. In one embodiment, the Solid dosage form is in the form of a lozenge adapted to be dissolved upon contact with Saliva in In accordance with another embodiment of the present invention an interferon pharmaceutical composition is for mulated for treating patients with fibromyalgia to provide a therapeutic response. In one embodiment the pharmaceutical composition comprises about 1 to about 1500 IU of interferon-alpha in combination with a Saliva Soluble carrier. More preferably, the pharmaceutical composition comprises about 5 to about 1000 IU of interferon-alpha in combination with a saliva soluble carrier. Most preferably, the pharma ceutical composition comprises about 15 to about 150 IU of interferon-alpha in combination with a Saliva Soluble carrier. A concentrated (20x) solution of phosphate buffered saline (PBS) was prepared by dissolving the following reagents in sufficient water to make 1,000 ml of solution: Sodium chloride, 160 grams, potassium chloride, 4.0 grams, Sodium hydrogen phosphate, 23 grams, potassium dihydro gen phosphate, 4.0 grams, and optionally phenol red powder, 0.4 grams. The Solution is Sterilized by autoclaving at 15 pounds pressure for 15 minutes and then diluted with additional water to a Single strength concentration prior to Sc. Alternatively the interferon for use in this invention by buccal, Sublingual or oral ingestion administration can be formulated into flavored or unflavored solutions or syrups using a buffered aqueous Solution of interferon as a base with added caloric or non-caloric Sweeteners, flavor oils and pharmaceutically acceptable Surfactant/dispersants. Solid dosage forms for oral ingestion administration can be pre pared using Standard tableting protocols and excipients to provide interferon-containing tablets, capsules, caplets, or gel Seals.
Interferon in a Solid dosage form can also be in the form of a lozenge adapted to be dissolved upon contact with Saliva in the mouth with or without the assistance of chewing. Such a unitary dosage form is formulated to release about 1 to about 1500 IU of interferon upon dissolution in the mouth for contact with the oral and pharyngeal mucosa. Thus a unitary dosage form of interferon in accordance with this invention can be prepared by art-recognized techniques for 6,036,949 S forming compressed tablets Such as chewable Vitamins. Similarly, interferon can be incorporated into Starch-based gel formulations to form a lozenge which will dissolve and release interferon for contact with the oral mucosa when held in the mouth. Solid unitary dosage forms of interferon for use in accordance with the present invention can be prepared utilizing art recognized dosage formulation tech niques. The pH of Such formulations can range from about 4 to about 8.5. Of course, in processing Such unitary dosage forms one should avoid heating a pre-dosage form formulation, after addition of interferon, above about 50 Centigrade.
The daily doses of interferon-alpha for administration in accordance with this invention can be administered as Single doses, or they can be divided and administered as a multiple dose daily regimen. Further, a Staggered regimen, for example, one to three days buccal/Sublingual interferon treatments per week, can be used as an alternative to daily treatment and for the purpose of defining this invention Such intermittent or Staggered daily regimen is considered to be equivalent to every day treatment and within the Scope of this invention. Medication. With only minor exceptions, all analgesic and Sedative hypnotic medications typically used for the treat ment of FMS were discontinued at the screening visit and proscribed for the entire duration of the study. Patients were permitted to take acetaminophen for Severe headache. In addition, low-dose 85 mg/day aspirin was allowed if previously prescribed for its anticoagulation therapy.
Enrolled patients were randomized into one of the coded Study medications. Each of the Study lozenges was prepared by Hayashibara Biochemical Laboratories Inc., Okayama, Japan), and contained IFN-C. at 15, 50 or 150 IU. The manufacturer also provided a placebo lozenge (OIU) which matched the IFN-C, lozenges in appearance and taste.
Administrations. Each participant was asked to dissolve one lozenge of IFN-C. Sublingually every morning for 6 weeks.
Outcome assessment. The participants had four clinical outcome assessments at two-week intervals over a six-week period. These were conducted without knowledge of the randomization code which was not revealed to the investi gators until after the last patient completed the Study and the -126 (1987) ). The tender point examinations were sys tematically performed by a single individual whose FMS examination skills had been previously validated and were periodically confirmed to correspond with that of an expe rienced FMS investigator.
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Clinical measures. The primary outcome variable was the tender point index (TPI), which is the sum of individual tenderness severities at each of the 18 standard ACR tender points. Three other variables were considered to be Second ary endpoints, including the patients' Self-assessment of global pain PAIN on a 10 cm visual analog scale VAS), subjective assessment of physical function by VAS FUNCTION), and the average pain threshold APT, mean value in Kg derived from dolorimeter readings at each of the 18 ACR tender points). Seven variables were considered to be tertiary endpoints including: the patient's VAS for head ache HEADACHE), the VAS for quality of sleep SLEEP), the VAS for global severity of morning stiffness STIFFNESS), the duration of morning stiffness, the Stan ford Health ASSessment Questionnaire HAO assessment of physical function ability, the Center for Epidemiology Stud ies Depression Questionnaire CESD), anxiety by the Hassles Scale HASSLES), and the concomitant use of proscribed analgesics ANALGESIC).
An intent-to-treat response in this study was defined as positive agent clinically beneficial if the patient experi enced at least a 30% reduction in the TPI and no worsening with regard to PAIN, FUNCTION, or APT.
Adverse effects. Adverse clinical events reported by the patients or noted by the investigational team were recorded at the assessment visits. Laboratory tests including complete blood count, Serum chemistry profile, and urinalysis were carried out on blood and urine Specimens at weeks Zero and four.
Sample size. Sample size needs were determined analyti cally. ASSuming a 17% mean for non-Specific improvement in the TPI among the placebo-treatment Subjects in a prior Study conducted by the same investigative team, it was determined that 23 evaluable patients in each group would Support a 94% power for detecting a 52% average improve ment (i.e. about 3-fold greater improvement than expected with placebo) in response to at least one of the IFN-C.
dosages. Since previous Studies with FMS patients docu mented a 20% loss-to-follow-up, it was considered prudent to enroll 28 patients per group in order to complete the Study with at least 23 evaluable patients per group.
Statistical analysis. ASSessment of treatment efficacy at any evaluation visit was based on within-patient differences (changes in outcome from baseline, week Zero, to the time of the evaluation visit, week two, week four, or week six).
For each outcome variable, three covariates were consid ered: age (dichotomized at the median, 47.9 years), race (Hispanic, Non-Hispanic Caucasian, and Other), and the week Zero value of the outcome variable (dichotomized on 6,036,949 7 the median as Low or High) to determine whether demo graphically definable Subgroups existed which were benefit ing from the treatment.
Then, Separate linear models were applied at each of the three follow-up evaluations to assess the Significance of 5 differences in outcome variable changes with time among the treatment groups 15 IU, 50 IU, 150 IU IFN-C com pared with placebo P. Possible adverse effects from IFN-C. and the influence of resuming proscribed medications during the course of the Study were assessed for Statistical signifi-10 cance by chi-square testing. All pairwise contrasts with placebo P vs 15 IU, P vs 50 IU, P vs 150 IU were examined. Results One hundred twenty four FMS patients were screened for 15 eligibility. Of those, 12 were not randomized because they proved not to have primary FMS N=2), not tolerate the washout N=21), or elected not to participate N=8). One hundred twelve patients qualified for Study participation. They exhibited a female: male ratio of 103:9, and a mean age 20 of 46.9 years. The ethnic distribution Hispanic 39.3% was Slightly different than the San Antonio general population about 60% Hispanic because of referrals to the investiga tor. Twenty eight Subjects were randomly assigned to each of the four treatment groups. 25 Ninety nine (88.4%) of the randomized subjects com pleted the week two assessment, 93 (83.0%) completed week four and 90 (80.4%) (placebo, N=20; 15 IU, N=25; 50 IU, N=23; 150 IU, N=22) completed the week six evaluation Only 19.6% of the randomized patients were lost to follow up before the end of the Study, confirming the accuracy of the pre-study power calculations and the loSS-to-follow-up predictions. Thus, the requirements of the Sample size cal culations were fully Satisfied. Chi-Square testing found no asSociation between treatment group and the occurrence of protocol Violations or loSS to follow-up.
The treatment responses for each of the outcome mea Sures are shown in Table 2 . According to the intent-to-treat analysis, the primary variable TPI failed to exhibit a Significant mean change from baseline to week Six among all of the groups receiving IFN-C. when compared with the placebo group. The same was true for the APT and subjec tive PAIN by VAS.
A significant improvement for global Severity of morning STIFFNESS by VAS was detected for FMS subjects in the 50 IU/day (P=0.03) and the 150 IU/day (P=0.05) IFN-C. treatment groups when compared with the placebo group. Pairwise treatment group contrasts for each Visit showed that this change was already evident at weeks two and four. Improvement in this variable at week six for subjects receiving 50 IU of IFN-O. per day was more apparent in Non-Hispanic Caucasians (mean=3.0, 95% CI=1.0, 5.1; P=0.005) than in Hispanics (mean=0.2, 95% CI=-3.6, 4.0; P=0.91) and in subjects older than the median 47.9 years (mean=3.0, 95% CI=0.5, 5.5, P=0.02) compared with the younger subgroup (mean=0.6, 95% CI=-1.8, 3.1; P=0.61). At best, Non-Hispanic Caucasians (N=68) with an aver age baseline STIFFNESS level (meaniSDI) of 6.65+2.39 (median=6.69, range 0.0-9.9) exhibited an average improvement of 3.0 units which represents a 45% improve ment over baseline. This was not a finding isolated to Non-Hispanic Caucasians with the 50 IU dosage of IFN-C, but was most dramatic with this combination of demography and dosage.
The Same analytic approach detected a near-significant (P=0.06) overall improvement in physical function ability averaged over time, as assessed by the HAO, in Subjects taking 50 IU/day of IFN-C compared with placebo. A progressive trend in the direction of improvement with time was evident which finally achieved significance (mean=0.3, 95% CI=0.0, 0.6, P=0.03) at week six. Significant improve ment was seen in younger patients age (age-47.9 years) (mean=0.5, 95% CI=0.0, -0.9; P=0.04) at week four and Non-Hispanic Caucasian patients (mean=0.15, 95% 0=0.1, 0.7, P=0.02) at week six.
At best, Non-Hispanic Caucasians (N=68) with an aver age baseline HAQ level (+SD) of 1.28+0.61, median=1.38 (range 0.0-2.63) exhibited an average improvement of 0.15 HAQ units which represents an 11.7% improvement over baseline.
All of the other Secondary, and tertiary outcome variables (e.g., VAS FUNCTION, PAIN, HEADACHE, SLEEP, CESD, HASSLES, ANALGESIC) failed to show significant improvement with any dosage of IFN-C.
Adverse events present during more than one evaluation were considered to be a single event. There were 105 events reported among 65 patients, So Some patients exhibited more than one. None were considered Serious, nor were any of the events judged by the physician to be "related," or even "probably related" to IFN-O. administration. Adverse events were quantitatively documented So they could be determined to have improved or worsened over time.
While the total numbers of individuals experiencing adverse gastrointestinal Symptoms was Small, patients tak ing the 15 IU/day IFN-Cl dosage were more likely to experience nausea and diarrhea than those on placebo. A borderline significant (P=0.07) change in the occurrence of diarrhea was found between the placebo-treated group (improved N=4, worsened N=0) and subjects in the 15 IU 
Discussion
Fibromyalgia syndrome FMS is a chronic, painful dis order commonly Seen in rheumatology practice. While it is often viewed as a musculoskeletal pain process, the most prominent biological abnormalities have been found in the levels of nociceptive neurotransmitters. The etiology of FMS is not known but consideration has been given to genetic, traumatic, affective, and infectious processes as possibilities. Clinicians typically employ combinations of education, medications, exercise, rest, and psychological Support; the resulting benefits are often disappointing.
In the past, there was a tendency to view FMS as a benign disorder which did not justify aggressive therapy which might carry with it any risk of adverse experience. However, that philosophy can no longer be justified considering the impact of this condition on the quality of life of affected individuals. Considering the annual cost S16 billion in direct cost alone of this disorder to the United States economy, innovative therapies for FMS must be considered and rigorously tested.
Interferon-C. was the first cytokine to be produced by recombinant DNA technology specifically for human administration. 90-94(1994) In a companion analysis of the data in this study, the APT was found to be a slightly more reliable outcome measure than the TPI, so the APT may have been a better choice as the primary outcome variable. Indeed, a trend (non significant) toward clinical benefit in the APT was observed with the 50 IU dosage. On the other hand, those findings were not Sufficiently dramatic to change the major conclu sions of the study with regard to IFN-C mono-therapy for FMS pain. Based on the effect size with APT in this study, we have estimated that reaching Significance on that variable would have required each of the comparison groups to contain 2000 individuals.
This study showed that the severity of morning stiffness decreased significantly with the 50 IU/day dosage of IFN-C. when compared with the placebo group. An average 45% reduction in the average Severity of the morning Stiffness is not trivial, especially since Some Subjects had much greater relief than the mean. In fact, the change in morning StiffneSS severity met the 30% criteria for clinically relevant improve ment. By contrast, cyclobenzaprine treatment of FMS resulted in a trend toward improvement in fatigue but morning stiffness was not affected (R. M. Bennett, R. A. With further study, IFN-C. may prove to be additively or even Synergistically beneficial with regard to morning Stiff neSS when combined as adjunctive treatment with concomi tant analgesic or Sedative hypnotic agent therapy.
It is not clear that the Slightly increased frequency of nausea and diarrhea seen with the lowest dosage of IFN-C. is properly attributed to IFN-C. because these side effects were not seen with the higher dosages.
It is of interest that Middleton, et al., studied 13 patients with chronic hepatitis C infection being treated with failed to find a significant improvement in the primary Study variable, the Tender Point Index or in two of the secondary variables, the APT and the global pain VAS. The improve ment in Stiffness represented a 45% reduction in morning stiffness with either 50 or 150 IU dosage levels. Though the improvement in physical function was a Statistically signifi cant improvement, it was less than the 30% improvement baseline Set for clinical relevance for the Study.
What is claimed:
1. A method for treating a human patient Suffering from fibromyalgia to produce a therapeutic response in Said patient, Said method comprising the Step of administering interferon buccally, Sublingually, or by oral ingestion at a dose of about 1 to about 1500 IU of interferon per day, provided that the patient is not infected with hepatitis C WUS.
2. The method of claim 1 wherein the interferon is administered at a dose of about 5 to about 1000 IU per day.
3. The method of claim 1 wherein the interferon is administered at a dose of about 10 to about 250 IU per day.
4. The method of claim 1 wherein the interferon is administered at a dose of about 15 to about 150 IU per day.
5. The method of claim 1, 2, 3 or 4 wherein the interferon is a Type I interferon.
6. The method of claim 5 wherein the interferon is interferon-alpha formulated in a pharmaceutically accept able Solid dosage form.
7. The method of claim 5 wherein the interferon is interferon-alpha formulated in a pharmaceutically accept able liquid dosage form.
8. The method of claim 6 wherein the solid dosage form is a Saliva-Soluble Solid dosage form of interferon-alpha which is administered by being introduced into the mouth of the patient and held in the mouth for a period of time sufficient to dissolve in saliva in the patient's mouth to form an interferon-containing Solution.
9. The method of claim 8 wherein the solid dosage form is a lozenge. 10. A method for treating a human patient Suffering from fibromyalgia to alleviate one or more clinical Symptoms of that disease, Said method comprising the Steps of Selecting a Saliva-Soluble lozenge dosage form of interferon-alpha, introducing the lozenge dosage form of interferon-alpha into the mouth of the patient, allowing the lozenge dosage form to dissolve in the patient's mouth to form an interferon-containing Solution, and contacting the interferon-containing Solution with the patient's oral and pharyngeal mucosa to Stimulate a therapeutic effect, wherein the interferon-alpha is administered to the patient in an amount of about 1 to about 1500 IU interferon per day, and provided that the patient is not infected with hepatitis C Virus. 11. A method for treating a human patient Suffering from fibromyalgia to alleviate one or more clinical Symptoms of that disease, Said method comprising the Step of contacting a pharmaceutically acceptable liquid formulation of interferon-alpha with the patient's oral and pharyngeal mucosa to Stimulate a Systemic therapeutic effect, wherein the interferon-alpha is administered to the patient in an amount of about 1 to about 1500 IU interferon per day, provided that the patient is not infected with hepatitis C WUS.
